Replies to post #156682 on Biotech Values

[ghmm]

DDXS / Lp-PLA2:

To answer your question from the other post yes I believe its theirs

http://www.plactest.com/healthcare/where-to-get-PLAC.html

Thanks for the info on the other GSK compound. diaDexus mentioned on a couple calls trying to grow revenues by utilizing the test in other areas and AD was one area. You may already know this for those of us that didn't they also said the marker is associated with inflammation.

I did buy DDXS knowing quite well that Darapladib Phase 3 results are quite risky based on mixed Phase 2 (at the very least GSK rushed into P3). I also know their IP situation isn't the greatest the comnpany indicated the ones not related to an inhibitor (like darapladib) extend to 2016 and some begin to expire either late this year or in 2014. If I felt better about these two things I would have probably bought a heck of a lot more though :-).

[DewDiligence]

Reuters profiles GSK’s Darapladib program, which is due to report phase-3 data any day:

http://finance.yahoo.com/news/crunch-time-glaxosmithklines-big-heart-142530908.html